| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
8,390,000 |
| Market
Cap: |
8.39(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.693 - $1 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Angion Biomedica is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapeutics to address chronic and progressive fibrotic diseases. Co.'s product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases. ANG-3070 has demonstrated activity as an anti-fibrotic agent in a variety of animal models. Co. is also continuing to develop its preclinical programs. Co.'s ROCK2 program, which is targeted towards the treatment of fibrotic diseases and CYP11B2 program, which is targeted towards diseases related to aldosterone synthase dysregulation.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
1,213,000 |
1,213,000 |
1,315,896 |
| Total Buy Value |
$0 |
$7,047,530 |
$7,047,530 |
$7,173,986 |
| Total People Bought |
0 |
1 |
1 |
3 |
| Total Buy Transactions |
0 |
1 |
1 |
6 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Gkcc, Llc |
10% Owner |
– – • |
2023-12-22 |
4 |
B |
$5.81 |
$7,047,530 |
I/I |
1,213,000 |
1,915,639 |
1.5 |
- |
|
| Haqq Christopher |
See Remarks |
• – – |
2023-06-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
31,981 |
|
- |
|
| Chudnovsky Yekaterina |
|
– • – |
2023-06-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
702,639 |
|
- |
|
| Connelly Robert |
CEO, President and Director |
• • – |
2023-06-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
46,970 |
|
- |
|
| Goldberg Itzhak |
Director |
– • – |
2022-07-01 |
4 |
D |
$1.12 |
$35,932 |
D/D |
(32,082) |
1,687,986 |
|
- |
|
| Venkatesan Jay |
See Remarks |
• • – |
2022-05-25 |
4 |
B |
$1.25 |
$14,103 |
D/D |
11,313 |
1,891,947 |
2.81 |
-21% |
|
| Venkatesan Jay |
See Remarks |
• • – |
2022-05-24 |
4 |
B |
$1.24 |
$39,928 |
D/D |
32,200 |
1,721,457 |
2.81 |
-24% |
|
| Venkatesan Jay |
See Remarks |
• • – |
2022-05-20 |
4 |
B |
$1.23 |
$61,500 |
D/D |
50,000 |
1,689,257 |
2.81 |
-28% |
|
| Nissenson Allen |
Director |
– • – |
2022-05-20 |
4 |
B |
$1.18 |
$2,404 |
D/D |
2,037 |
9,383 |
2.31 |
-28% |
|
| Nissenson Allen |
Director |
– • – |
2022-05-19 |
4 |
B |
$1.16 |
$8,521 |
D/D |
7,346 |
7,346 |
2.39 |
-27% |
|
| Venkatesan Jay |
See Remarks |
• • – |
2021-12-28 |
4 |
B |
$2.66 |
$559,854 |
D/D |
210,337 |
1,639,257 |
2.81 |
-39% |
|
| Venkatesan Jay |
See Remarks |
• • – |
2021-12-27 |
4 |
B |
$2.55 |
$170,519 |
D/D |
66,907 |
1,428,920 |
2.81 |
-40% |
|
| Venkatesan Jay |
See Remarks |
• • – |
2021-12-20 |
4 |
B |
$2.54 |
$8,976 |
D/D |
3,527 |
1,362,013 |
2.81 |
-50% |
|
| Neylan John F. |
See Remarks |
• – – |
2021-12-20 |
4 |
AS |
$2.62 |
$938 |
D/D |
(358) |
35,136 |
|
-50% |
|
| Venkatesan Jay |
See Remarks |
• • – |
2021-12-17 |
4 |
B |
$2.54 |
$34,958 |
D/D |
13,742 |
1,358,486 |
2.81 |
-51% |
|
| Venkatesan Jay |
See Remarks |
• • – |
2021-12-16 |
4 |
B |
$2.55 |
$70,993 |
D/D |
27,883 |
1,344,744 |
2.81 |
-50% |
|
| Venkatesan Jay |
See Remarks |
• • – |
2021-12-15 |
4 |
B |
$2.41 |
$186,956 |
D/D |
77,604 |
1,316,861 |
2.81 |
-49% |
|
| Curhan Gregory S |
See Remarks |
• – – |
2021-12-15 |
4 |
B |
$2.37 |
$9,480 |
D/D |
4,000 |
4,000 |
2.74 |
-49% |
|
| Rhodes Jennifer J |
See Remarks |
• – – |
2021-12-14 |
4 |
AS |
$2.42 |
$1,090 |
D/D |
(451) |
30,399 |
|
-42% |
|
| Goldberg Itzhak |
See Remarks |
• • – |
2021-12-06 |
4 |
AS |
$3.35 |
$107,721 |
D/D |
(32,118) |
1,720,068 |
|
-49% |
|
| Goldberg Itzhak |
See Remarks |
• • – |
2021-12-03 |
4 |
AS |
$3.39 |
$136,216 |
D/D |
(40,215) |
1,752,186 |
|
-48% |
|
| Goldberg Itzhak |
See Remarks |
• • – |
2021-12-02 |
4 |
AS |
$3.51 |
$136,328 |
D/D |
(38,800) |
1,792,401 |
|
-48% |
|
| Goldberg Itzhak |
See Remarks |
• • – |
2021-12-01 |
4 |
AS |
$3.54 |
$137,667 |
D/D |
(38,867) |
1,831,201 |
|
-47% |
|
| Goldberg Itzhak |
See Remarks |
• – – |
2021-11-16 |
4 |
AS |
$4.26 |
$163,808 |
D/D |
(38,495) |
1,870,068 |
|
-52% |
|
| Goldberg Itzhak |
See Remarks |
• – – |
2021-11-15 |
4 |
AS |
$4.17 |
$465,243 |
D/D |
(111,505) |
1,908,563 |
|
-47% |
|
70 Records found
|
|
Page 1 of 3 |
|
|
